{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:55:36Z","timestamp":1787972136478,"version":"build-2784847793"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFA0908004"],"award-info":[{"award-number":["2020YFA0908004"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82293684"],"award-info":[{"award-number":["82293684"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204410"],"award-info":[{"award-number":["82204410"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113040","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T23:46:29Z","timestamp":1725061589000},"page":"113040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"PA","title":["Bruton\u2019s tyrosine kinase: A promising target for treating systemic lupus erythematosus"],"prefix":"10.1016","volume":"142","author":[{"given":"Qiaoyi","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.113040_b0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study","volume":"82","author":"Tian","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.113040_b0010","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1016\/j.apsb.2023.07.026","article-title":"JAK inhibition ameliorated experimental autoimmune encephalomyelitis by blocking GM-CSF-driven inflammatory signature of monocytes","volume":"13","author":"Shao","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.intimp.2024.113040_b0015","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1016\/j.apsb.2023.04.003","article-title":"Bone-derived MSCs encapsulated in alginate hydrogel prevent collagen-induced arthritis in mice through the activation of adenosine A(2A\/2B) receptors in tolerogenic dendritic cells","volume":"13","author":"Shi","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.intimp.2024.113040_b0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12519-019-00229-3","article-title":"Immunological pathogenesis and treatment of systemic lupus erythematosus","volume":"16","author":"Pan","year":"2020","journal-title":"World J. Pediatr."},{"key":"10.1016\/j.intimp.2024.113040_b0025","doi-asserted-by":"crossref","first-page":"eabo4363","DOI":"10.1126\/sciadv.abo4363","article-title":"A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing gammac cytokine-related JAK-STAT signal","volume":"8","author":"Chen","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.intimp.2024.113040_b0030","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149095","article-title":"Meant to B: B cells as a therapeutic target in systemic lupus erythematosus","volume":"131","author":"Atisha-Fregoso","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2024.113040_b0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/cmi.2012.64","article-title":"B-cell-targeted therapies in systemic lupus erythematosus","volume":"10","author":"Chan","year":"2013","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2024.113040_b0040","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1182\/blood-2011-12-397919","article-title":"Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice","volume":"119","author":"Kil","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2024.113040_b0045","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.molimm.2008.08.278","article-title":"Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells","volume":"46","author":"Halcomb","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.intimp.2024.113040_b0050","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.3389\/fimmu.2017.01986","article-title":"Bruton's Tyrosine Kinase, a Component of B Cell Signaling Pathways Has Multiple Roles in the Pathogenesis of Lupus","volume":"8","author":"Satterthwaite","year":"2017","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2024.113040_b0055","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40265-023-01856-x","article-title":"Targeted small molecules for systemic lupus erythematosus: drugs in the pipeline","volume":"83","author":"Mok","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2024.113040_b0060","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13075-024-03331-8","article-title":"Efficacy and safety study of targeted small-molecule drugs in the treatment of systemic lupus erythematosus","volume":"26","author":"Wang","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2024.113040_b0065","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1038\/sj.onc.1203958","article-title":"Signaling network of the Btk family kinases","volume":"19","author":"Qiu","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2024.113040_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113329","article-title":"Emerging small-molecule inhibitors of the Bruton\u2019s Tyrosine Kinase (BTK): current development","volume":"217","author":"Liu","year":"2021","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.intimp.2024.113040_b0075","first-page":"610","article-title":"Genetic defect in human X-linked agammaglobulinemia impedes a maturational evolution of pro-B cells into a later stage of pre-B cells in the B-cell differentiation pathway","volume":"96","author":"Nomura","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2024.113040_b0080","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/bies.1062","article-title":"The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species","volume":"23","author":"Smith","year":"2001","journal-title":"Bioessays"},{"key":"10.1016\/j.intimp.2024.113040_b0085","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13543776.2019.1594777","article-title":"Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010\u20132018)","volume":"29","author":"Feng","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.intimp.2024.113040_b0090","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2024.113040_b0095","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1074-7613(00)80204-6","article-title":"LAT is essential for Fc\u03b5RI-mediated mast cell activation","volume":"12","author":"Saitoh","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2024.113040_b0100","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nri1782","article-title":"Integrated signalling pathways for mast-cell activation","volume":"6","author":"Gilfillan","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2024.113040_b0105","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1111\/j.1742-4658.2011.08073.x","article-title":"Tec family kinases: regulation of Fc\u03b5RI-mediated mast-cell activation","volume":"278","author":"Ellmeier","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.intimp.2024.113040_b0110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nchembio.481","article-title":"Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis","volume":"7","author":"Di Paolo","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.intimp.2024.113040_b0115","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4049\/jimmunol.181.1.288","article-title":"Dual functions of Bruton's tyrosine kinase and Tec kinase during Fc\u03b3 receptor-induced signaling and phagocytosis","volume":"181","author":"Jongstra-Bilen","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.113040_b0120","doi-asserted-by":"crossref","first-page":"26258","DOI":"10.1074\/jbc.M301484200","article-title":"Bruton's tyrosine kinase is a Toll\/interleukin-1 receptor domain-binding protein that participates in NF-\u03baB activation by Toll-like receptor 4","volume":"278","author":"Jefferies","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2024.113040_b0125","doi-asserted-by":"crossref","first-page":"7360","DOI":"10.1038\/ncomms8360","article-title":"Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury","volume":"6","author":"Ito","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2024.113040_b0130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","article-title":"Bruton's tyrosine kinase and phospholipase C\u03b32 mediate chemokine-controlled B cell migration and homing","volume":"26","author":"de Gorter","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2024.113040_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102861","article-title":"Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target","volume":"132","author":"Lou","year":"2022","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2024.113040_b0140","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/imr.12821","article-title":"Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies","volume":"292","author":"Meffre","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2024.113040_b0145","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.celrep.2017.01.050","article-title":"BCR and endosomal TLR signals synergize to increase AID expression and establish central B cell tolerance","volume":"18","author":"Kuraoka","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2024.113040_b0150","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10067-017-3717-3","article-title":"Increased expression of Bruton's tyrosine kinase in peripheral blood is associated with lupus nephritis","volume":"37","author":"Kong","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2024.113040_b0155","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jbspin.2020.05.004","article-title":"Bruton's tyrosine kinase in systemic lupus erythematosus","volume":"87","author":"Liao","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.intimp.2024.113040_b0160","doi-asserted-by":"crossref","DOI":"10.1111\/pim.12455","article-title":"IL-6 promotes CD4(+) T-cell and B-cell activation during plasmodium infection","volume":"39","author":"Sebina","year":"2017","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.intimp.2024.113040_b0165","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1084\/jem.20170580","article-title":"B cell-derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity","volume":"214","author":"Arkatkar","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2024.113040_b0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246231","article-title":"B cell abnormalities in systemic lupus erythematosus and lupus nephritis-role in pathogenesis and effect of immunosuppressive treatments","volume":"20","author":"Yap","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.113040_b0175","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fimmu.2019.00095","article-title":"Toll-like receptor signaling drives Btk-mediated autoimmune disease","volume":"10","author":"Rip","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2024.113040_b0180","doi-asserted-by":"crossref","first-page":"e74103","DOI":"10.1371\/journal.pone.0074103","article-title":"Bruton's tyrosine kinase mediates the synergistic signalling between TLR9 and the B cell receptor by regulating calcium and calmodulin","volume":"8","author":"Kenny","year":"2013","journal-title":"Plos One"},{"key":"10.1016\/j.intimp.2024.113040_b0185","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3389\/fimmu.2017.01454","article-title":"Bruton's tyrosine kinase: an emerging key player in innate immunity","volume":"8","author":"Weber","year":"2017","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2024.113040_b0190","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ni.2015","article-title":"Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk","volume":"12","author":"Liu","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2024.113040_b0195","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.2174\/0929867325666180316121951","article-title":"Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis","volume":"25","author":"Lv","year":"2018","journal-title":"Curr. Med Chem."},{"key":"10.1016\/j.intimp.2024.113040_b0200","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.intimp.2024.113040_b0205","doi-asserted-by":"crossref","first-page":"R243","DOI":"10.1186\/ar4086","article-title":"Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus","volume":"14","author":"Hutcheson","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2024.113040_b0210","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","article-title":"Orelabrutinib: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2024.113040_b0215","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1182\/bloodadvances.2022009168","article-title":"Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1\/2, open-label, multicenter, single-arm study","volume":"7","author":"Deng","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2024.113040_b0220","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/17460441.2023.2236547","article-title":"The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies","volume":"18","author":"Robak","year":"2023","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.intimp.2024.113040_b0225","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1021\/acs.jmedchem.9b00167","article-title":"Discovery of branebrutinib (BMS-986195): a strategy for identifying a highly potent and selective covalent inhibitor providing rapid in vivo inactivation of Bruton's tyrosine kinase (BTK)","volume":"62","author":"Watterson","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2024.113040_b0230","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1080\/14397595.2018.1484269","article-title":"ABBV-105, a selective and irreversible inhibitor of Bruton's tyrosine kinase, is efficacious in multiple preclinical models of inflammation","volume":"29","author":"Goess","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.intimp.2024.113040_b0235","first-page":"CD007478","article-title":"Interventions for cutaneous disease in systemic lupus erythematosus","volume":"3","author":"Hannon","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.intimp.2024.113040_b0240","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.4049\/jimmunol.1800583","article-title":"Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models","volume":"202","author":"Haselmayer","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.113040_b0245","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00401-020-02204-z","article-title":"Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease","volume":"140","author":"Torke","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.intimp.2024.113040_b0250","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.3324\/haematol.2019.220590","article-title":"Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma","volume":"105","author":"Flinsenberg","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2024.113040_b0255","doi-asserted-by":"crossref","first-page":"26164","DOI":"10.1038\/srep26164","article-title":"Therapeutic blockade of immune complex-mediated glomerulonephritis by highly selective inhibition of Bruton's tyrosine kinase","volume":"6","author":"Chalmers","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2024.113040_b0260","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.clim.2018.10.008","article-title":"BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis","volume":"197","author":"Chalmers","year":"2018","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2024.113040_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108640","article-title":"BTK inhibition modulates multiple immune cell populations involved in the pathogenesis of immune mediated nephritis","volume":"223","author":"Chalmers","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2024.113040_b0270","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/cpt.1056","article-title":"Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers treated with GDC-0853, a selective reversible Bruton's tyrosine kinase inhibitor","volume":"103","author":"Herman","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2024.113040_b0275","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acs.jmedchem.7b01712","article-title":"Discovery of GDC-0853: a potent, selective, and noncovalent Bruton's tyrosine kinase inhibitor in early clinical development","volume":"61","author":"Crawford","year":"2018","journal-title":"J. Med Chem."},{"key":"10.1016\/j.intimp.2024.113040_b0280","first-page":"1835","article-title":"Efficacy, safety, and pharmacodynamic effects of the Bruton's tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a Phase II, randomized, double-blind, placebo-controlled trial, Arthritis","volume":"73","author":"Isenberg","year":"2021","journal-title":"Rheumatol."},{"key":"10.1016\/j.intimp.2024.113040_b0285","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/bcp.14290","article-title":"Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants","volume":"86","author":"Catlett","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113040_b0290","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J. Med Chem."},{"key":"10.1016\/j.intimp.2024.113040_b0295","first-page":"e30330","article-title":"An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management","volume":"14","author":"Ameer","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.intimp.2024.113040_b0300","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update omicronn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.113040_b0305","first-page":"99","article-title":"Signaling lymphocytic activation molecule family member 1 engagement inhibits T cell-B cell interaction and diminishes interleukin-6 production and plasmablast differentiation in systemic lupus erythematosus, Arthritis","volume":"71","author":"Karampetsou","year":"2019","journal-title":"Rheumatol."},{"key":"10.1016\/j.intimp.2024.113040_b0310","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/eji.201545760","article-title":"T follicular helper (Tfh) cells in lupus: activation and involvement in SLE pathogenesis","volume":"46","author":"Blanco","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2024.113040_b0315","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.18418","article-title":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"200","author":"Nakhoda","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2024.113040_b0320","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.intimp.2024.113040_b0325","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupinan","year":"2021","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.intimp.2024.113040_b0330","article-title":"Investigating bleeding adverse events associated with BTK inhibitors in the food and drug administration adverse event reporting system (FAERS)","volume":"1\u201310","author":"Li","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.intimp.2024.113040_b0335","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051103","article-title":"Bleeding by Bruton tyrosine kinase-inhibitors: dependency on drug type and disease","volume":"13","author":"von Hundelshausen","year":"2021","journal-title":"Cancers (basel)"},{"key":"10.1016\/j.intimp.2024.113040_b0340","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","article-title":"Dermatological toxicities of Bruton's tyrosine kinase inhibitors","volume":"21","author":"Sibaud","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.intimp.2024.113040_b0345","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jaad.2019.12.031","article-title":"Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events","volume":"88","author":"Singer","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2024.113040_b0350","doi-asserted-by":"crossref","DOI":"10.1177\/2040620721990553","article-title":"The role of acalabrutinib in adults with chronic lymphocytic leukemia","volume":"12","author":"Fakhri","year":"2021","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.intimp.2024.113040_b0355","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40265-023-01860-1","article-title":"Pirtobrutinib: First Approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2024.113040_b0360","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2159-8290.CD-23-0670","article-title":"First-in-human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma","volume":"14","author":"Woyach","year":"2024","journal-title":"Cancer Discov."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924015613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924015613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:58:00Z","timestamp":1778619480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924015613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":72,"alternative-id":["S1567576924015613"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113040","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bruton\u2019s tyrosine kinase: A promising target for treating systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113040"}}